公开(公告)号：JPH06296496A

公开(公告)日：1994-10-25

申请号：JP26909393

申请日：1993-10-27

Applicant: INAMOTO HAJIME ,  FUSO PHARMACEUTICAL IND

Inventor： INAMOTO HAJIME ,  SEGAWA TOMOKAZU ,  KUNITO KAZUYA ,  MATSUKAWA AKIRA

IPC: A61K39/395 ,  C12N5/10 ,  C12N5/20 ,  C12N15/02 ,  C12N15/06 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53 ,  G01N33/577

Abstract: PURPOSE:To afford a hybridoma producing a monoclonal antibody to be used in the assay of nephropathies by measurement of urinary kidney antigen. CONSTITUTION:Antibody-producing mammalian cells immunized with normal human renal tissue or HeLa cells are fused with myeloma cells to give the objective hybridoma cells.

公开(公告)号：JPS63177798A

公开(公告)日：1988-07-21

申请号：JP878587

申请日：1987-01-16

Applicant: FUSO PHARMACEUTICAL IND ,  INAMOTO HAJIME

Inventor： MATSUKAWA AKIRA ,  SEGAWA TOMOKAZU ,  KUNITO KAZUYA ,  INAMOTO HAJIME

IPC: C12N15/02 ,  C07K14/005 ,  C07K14/195 ,  C07K16/00 ,  C07K19/00 ,  C12N5/00 ,  C12N5/10 ,  C12N15/00 ,  C12P21/00 ,  C12P21/08 ,  C12R1/91 ,  G01N33/574 ,  G01N33/577

Abstract: NEW MATERIAL:An antibody showing specificity to an antigen determinant of a cell of human carcinoma of uterine. USE:A reagent for detecting a cell of carcinoma of uterine. PREPARATION:For example, a mammal such as mouse, etc., is inoculated and immunized against a cell of human carcinoma of uterine, an antibody-forming cell is collected from the spleen, which is subjected to cell fusion with a permanently multiplying cell and cultivated in HAT medium to give a hybridoma. Then the hybridoma is screened, a clone to produce an antigen to specifically react with a cell of carcinoma of uretine is selected and cloned by limiting dilution method into a monoclone. Further the monoclonal hybridoma is cultivated to give a monoclonal antibody.

公开(公告)号：JPS63112994A

公开(公告)日：1988-05-18

申请号：JP25965586

申请日：1986-10-31

Applicant: INAMOTO HAJIME ,  FUSO PHARMACEUTICAL IND

Inventor： INAMOTO HAJIME ,  SEGAWA TOMOKAZU ,  KUNITO KAZUYA ,  MATSUKAWA AKIRA

IPC: C12N15/02 ,  C07K14/005 ,  C07K14/195 ,  C07K16/00 ,  C07K16/18 ,  C12N5/00 ,  C12N5/10 ,  C12N15/00 ,  C12P21/00 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53 ,  G01N33/577

Abstract: PURPOSE:To measure an amount of antigen discharged in urine and to specify a disorder site, by preparing a monoclonal antibody to be specifically reacted with a human normal renal tissue antigen such as human lumen wall of renal uriniferous tubule, basement membrane of glomerulus, etc. CONSTITUTION:An antibody-forming cell of an animal immunized against a normal human renal tissue or Hela cell is fused with a myeloma cell to give a hybridoma, which is cultivated to produce a normal human renal tissue. A monoclonal antibody to be specifically reacted with the normal human renal tissue is recovered to produce a monoclonal antibody. A disorder site in the kidney and the degree of the disorder are diagnosed by measuring an antigen in urine by using the monoclonal antibody to specifically recognize the human normal renal tissue antigen. The diagnose is carried out by comparing a measured value of antigen in specimen urine with a value of antigen in normal human urine.

公开(公告)号：JP2000002703A

公开(公告)日：2000-01-07

申请号：JP16828598

申请日：1998-06-16

Applicant: FUSO PHARMACEUTICAL IND

Inventor： UEMURA HIDETOSHI ,  KISHI YUICHIRO ,  KUNITO KAZUYA ,  HIROOKA YUMI

IPC: G01N33/50 ,  A61K9/16 ,  A61K39/395 ,  C07K16/18 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543

Abstract: PROBLEM TO BE SOLVED: To judge the diagnosis and critical degree of renal disease by bringing a second antibody having a labeled molecule connected thereto into contact with a biological sample and a subject having a first antibody brought into contact with the surface of a solid granule, and detecting the labeled molecule connected to a complement control factor. SOLUTION: With respect to urine and serum of a normal person and a renal disease patient, MCP quantity (membrane cofactor protein) is measured. A magnetic bead having a monoclonal antibody 177, a subject and a POD labeled monoclonal antibody M160 are reacted to focus and fix the bead by the magnet, and the supernatant is disposed. After washing, a substrate solution is added to further react them, and the bead is focused and fixed by the magnet, and the supernatant is collected to measure the absorbance. The serum MCP value is measured by use of the monoclonal antibody M160 and also by use of the POD labeled monoclonal antibody M160 as the detecting antibody. As a result of the measurement, the MCP values in urine and serum are distributed in high level in the renal disease patient, compared with the normal person, and also high in a more critical patient.